Cyclacel Pharmaceuticals, Inc. Revenue 2024–2025
Cyclacel Pharmaceuticals, Inc. annual/quarterly revenue history and growth rate from 2024 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Cyclacel Pharmaceuticals, Inc. revenue for the quarter ending March 31, 2026 was 778000.
- Cyclacel Pharmaceuticals, Inc. revenue for the twelve months ending March 31, 2026 was 1.5 M.
- Cyclacel Pharmaceuticals, Inc. annual revenue for 2025 was 747000, a 1637.21% increase from 2024.
- Cyclacel Pharmaceuticals, Inc. annual revenue for 2024 was 43000.
Cyclacel Pharmaceuticals, Inc. (BGMS) — Frequently Asked Questions
Cyclacel Pharmaceuticals, Inc. (BGMS) is a publicly traded US company. It has a market capitalization of $2M. In fiscal 2025 it reported revenue of $747,000 and net income of -$3M. Explore BGMS's stock price, financial statements, earnings history, margins and key ratios below.
What is Cyclacel Pharmaceuticals, Inc.'s market cap?
Cyclacel Pharmaceuticals, Inc. (BGMS) has a market capitalization of $2M.
What is the BGMS stock price?
BGMS trades at $0.91 (+1.01% on the day).
How much revenue does Cyclacel Pharmaceuticals, Inc. make?
Cyclacel Pharmaceuticals, Inc. reported revenue of $747,000 in fiscal 2025.
Is BGMS profitable?
In fiscal 2025, Cyclacel Pharmaceuticals, Inc. reported net income of -$3M.